Evaluation of hemodynamic parameters among patients with myeloproliferative neoplasms and suspected pulmonary hypertension

References

• Mehari A, Valle O, Gillum RF. Trends in pulmonary hypertension mortality and morbidity. Pulm Med. 2014;2014:105864.
   PubMedGoogle Scholar
• Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2018;53(1):1801913.
   Web of Science ®Google Scholar
• Gupta R, Perumandla S, Patsiornik Y, et al. Incidence of pulmonary hypertension in patients with chronic myeloproliferative disorders. J Natl Med Assoc. 2006;98(11):1779–1782.
   PubMed Web of Science ®Google Scholar
• Reisner SA, Rinkevich D, Markiewicz W, et al. Cardiac involvement in patients with myeloproliferative disorders. Am J Med. 1992;93(5):498–504.
   PubMed Web of Science ®Google Scholar
• Altintas A, Karahan Z, Pasa S, et al. Pulmonary hypertension in patients with essential thrombocythemia and reactive thrombocytosis. Leuk Lymphoma. 2007;48(10):1981–1987.
   PubMed Web of Science ®Google Scholar
• Garypidou V, Vakalopoulou S, Dimitriadis D, et al. Incidence of pulmonary hypertension in patients with chronic myeloproliferative disorders. Haematologica. 2004;89(2):245–246.
   PubMed Web of Science ®Google Scholar
• Cortelezzi A, Gritti G, Del Papa N, et al. Pulmonary arterial hypertension in primary myelofibrosis is common and associated with an altered angiogenic status. Leukemia. 2008;22(3):646–649.
   PubMed Web of Science ®Google Scholar
• Chebrek S, Aissi K, Francès Y, et al. Pulmonary hypertension in patients with chronic myeloproliferative neoplasms (MPN). Leuk Lymphoma. 2014;55(1):223–235. http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=23614764&retmode=ref&cmd=prlinks%5Cnpapers3://publication/doi/10.3109/10428194.2013.797083.
   PubMed Web of Science ®Google Scholar
• Roach EC, Park MM, Wilson Tang WH, et al. Impaired right ventricular-pulmonary vascular function in myeloproliferative neoplasms. J Hear Lung Transplant. 2015;34(3):390–394.
   PubMed Web of Science ®Google Scholar
• Brabrand M, Hansen KN, Laursen CB, et al. Frequency and etiology of pulmonary hypertension in patients with myeloproliferative neoplasms. Eur J Haematol. 2019;102(3):227–234.
   PubMed Web of Science ®Google Scholar
• Venton G, Turcanu M, Colle J, et al. Pulmonary hypertension in patients with myeloproliferative neoplasms: a large cohort of 183 patients. Eur J Intern Med. 2019;68:71–75.
   PubMed Web of Science ®Google Scholar
• Fisher MR, Forfia PR, Chamera E, et al. Accuracy of doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med. 2009;179(7):615–621.
   PubMed Web of Science ®Google Scholar
• Galiè N, Humbert M, Vachiery J-L, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37(1):67–119.
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 Expert consensus document on pulmonary hypertension. Circulation. 2009;119(16):2250–2294. http://circ.ahajournals.org/content/119/16/2250.abstract.
   Google Scholar
• D'Alto M, Romeo E, Argiento P, et al. Accuracy and precision of echocardiography versus right heart catheterization for the assessment of pulmonary hypertension. Int J Cardiol. 2013;168(4):4058–4062.
   PubMed Web of Science ®Google Scholar
• Rich JD, Shah SJ, Swamy RS, et al. Inaccuracy of Doppler echocardiographic estimates of pulmonary artery pressures in patients with pulmonary hypertension: Implications for clinical practice. Chest. 2011;139(5):988–993.
   PubMed Web of Science ®Google Scholar
• Lawrence GR, Wyman WL,Afilalo J, et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography. J Am Soc Echocardiogr. 2010;23(7):685–713.
   PubMed Web of Science ®Google Scholar
• Landolfi R, Di Gennaro L, Falanga A. Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation. Leukemia. 2008;22(11):2020–2028.
   PubMed Web of Science ®Google Scholar
• Kwaan HC, Wang J. Hyperviscosity in polycythemia vera and other red cell abnormalities. Semin Thromb Hemost. 2003;29(5):451–458.
   PubMed Web of Science ®Google Scholar
• Huang PY, Hellums JD. Aggregation and disaggregation kinetics of human blood platelets: Part III. The disaggregation under shear stress of platelet aggregates. Biophys J. 1993;65(1):354–361.
   PubMed Web of Science ®Google Scholar
• Steensma DP, Hook CC, Stafford SL, et al. Low-dose, single-fraction, whole-lung radiotherapy for pulmonary hypertension associated with myelofibrosis with myeloid metaplasia. Br J Haematol. 2002;118(3):813–816.
   PubMed Web of Science ®Google Scholar
• Adir Y, Elia D, Harari S. Pulmonary hypertension in patients with chronic myeloproliferative disorders. Eur Respir Rev. 2015;24(137):400–410.
   PubMed Web of Science ®Google Scholar
• Hill G, McClean D, Fraser R, et al. Pulmonary hypertension as a consequence of alveolar capillary plugging by malignant megakaryocytes in essential thrombocythaemia. Aust NZ J Med. 1996;26(6):852–853.
   Google Scholar
• Marvin KS, Spellberg RD. Pulmonary hypertension secondary to thrombocytosis in a patient with myeloid metaplasia. Chest. 1993;103(2):642–644.
   PubMed Web of Science ®Google Scholar
• Rostagno C, Prisco D, Abbate R, et al. Pulmonary hypertension associated with long-standing thrombocytosis. Chest. 1991;99(5):1303–1305.
   PubMed Web of Science ®Google Scholar
• White SM, Wagner JG, Roth RA. Effects of altered platelet number on pulmonary hypertension and platelet sequestration in monocrotaline pyrrole-treated rats. Toxicol Appl Pharmacol. 1989;99(2):302–313.
   Web of Science ®Google Scholar
• Shishido N, Inoue A, Morishita H, et al. A case of chronic thromboembolic pulmonary hypertension based on essential thrombocythemia. Nihon Kokyuki Gakkai Zasshi. 2002;40(7):574–578.
   PubMedGoogle Scholar
• Demerouti E, Manginas A, Leontiadis E, et al. A 53-year-old woman with thrombocytosis and pulmonary embolism. Arch Med Sci. 2014;10(1):191–194.
   PubMed Web of Science ®Google Scholar
• Magge A, Kaiser T, Mutneja R, et al. Chronic thromboembolic pulmonary hypertension in the setting of essential thrombocytosis. Chest. 2016;150(4):1226A.
   Web of Science ®Google Scholar
• Dingli D, Utz JP, Krowka MJ, et al. Unexplained pulmonary hypertension in chronic myeloproliferative disorders. Chest. 2001;120(3):801–808.
   PubMed Web of Science ®Google Scholar
• Guilpain P, Montani D, Damaj G, et al. Pulmonary hypertension associated with myeloproliferative disorders: a retrospective study of ten cases. Respiration. 2008;76(3):295–302.
   PubMed Web of Science ®Google Scholar
• Birgegard G. Advances and challenges in the management of essential thrombocythemia. Ther Adv Hematol. 2015;6(3):142–156.
   PubMed Web of Science ®Google Scholar
• Adatia I, Barrow SE, Stratton PD, et al. Thromboxane A2 and prostacyclin biosynthesis in children and adolescents with pulmonary vascular disease. Circulation. 1993;88(5):2117–2122.
   PubMed Web of Science ®Google Scholar
• Christman BW, Mcpherson CD, Newman JH, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med. 1992;327(2):70–75.
   PubMed Web of Science ®Google Scholar
• Welsh DJ, Harnett M, MacLean M, et al. Proliferation and signaling in fibroblasts: role of 5-hydroxytryptamine2a receptor and transporter. Am J Respir Crit Care Med. 2004;170(3):252–259.
   PubMed Web of Science ®Google Scholar
• Marcos E, Fadel E, Sanchez O, et al. Serotonin-induced smooth muscle hyperplasia in various forms of human pulmonary hypertension. Circ Res. 2004;94(9):1263–1270.
   PubMed Web of Science ®Google Scholar
• Liu Y, Li M, Warburton RR, et al. The 5‐HT transporter transactivates the PDGFβ receptor in pulmonary artery smooth muscle cells. FASEB J. 2007;21(11):2725–2734.
   PubMed Web of Science ®Google Scholar
• Adnot S, Eddahibi S, Grosgogeat Y, et al. Pathobiology of pulmonary artery hypertension. Bull Acad Natl Med. 2002;20(6):1559–1572.
   Web of Science ®Google Scholar
• MacLean MR, Dempsie Y. The serotonin hypothesis of pulmonary hypertension revisited. Advances Exp Med Biol. 2010;661:309–322.
   PubMed Web of Science ®Google Scholar
• Humbert M, Monti G, Fartoukh M, et al. Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. Eur Respir J. 1998;11(3):554–559.
   Web of Science ®Google Scholar
• Spivak JL. Polycythemia Vera. Curr Treat Options Oncol. 2018;19(2):12.
   PubMed Web of Science ®Google Scholar
• Zetterberg E, Popat U, Hasselbalch H, et al. Angiogenesis in pulmonary hypertension with myelofibrosis. Haematologica. 2008;93(6):945–946.
   PubMed Web of Science ®Google Scholar
• Mathew R, Huang J, Wu JM, et al. Hematological disorders and pulmonary hypertension. World J Cardiol. 2016;8(12):703–718.
   PubMed Web of Science ®Google Scholar
• Singh I, Mikita G, Green D, et al. Pulmonary extra-medullary hematopoiesis and pulmonary hypertension from underlying polycythemia vera: a case series. Pulm Circ. 2017;7(1):261–267.
   PubMed Web of Science ®Google Scholar
• Ali SZ, Clarke MJ, Kannivelu A, et al. Extramedullary pulmonary hematopoiesis causing pulmonary hypertension and severe tricuspid regurgitation detected by technetium-99m sulfur colloid bone marrow scan and single-photon emission computed tomography/CT. Korean J Radiol. 2014;15(3):376–380.
   PubMed Web of Science ®Google Scholar
• Weinschenker P, Kutner JM, Salvajoli JV, et al. Whole-pulmonary low-dose radiation therapy in agnogenic myeloid metaplasia with diffuse lung involvement. Am J Hematol. 2002;69:277–280.
   PubMed Web of Science ®Google Scholar
• Willems E, Canivet J-L, Ghaye B, et al. Pulmonary veno-occlusive disease in myeloproliferative disorder. Eur Respir J. 2009;33(1):213–216.
   PubMed Web of Science ®Google Scholar
• Tachibana T, Nakayama N, Matsumura A, et al. Pulmonary hypertension associated with pulmonary veno-occlusive disease in patients with polycythemia vera. Intern Med. 2017;56(18):2487–2492.
   Web of Science ®Google Scholar
• Popat U, Frost A, Liu E, et al. New onset of myelofibrosis in association with pulmonary arterial hypertension. Ann Intern Med. 2005;143(6):466.
   PubMed Web of Science ®Google Scholar
• Fadini GP, Schiavon M, Cantini M, et al. Circulating CD34+ cells, pulmonary hypertension, and myelofibrosis. Blood. 2006;108(5):1776–1777.
   PubMed Web of Science ®Google Scholar
• Lopez-Mattei J, Verstovsek S, Fellman B, et al. Prevalence of pulmonary hypertension in myelofibrosis. Ann Hematol. 2020;99(4):781–789.
   PubMed Web of Science ®Google Scholar
• Mughal TI, Vaddi K, Sarlis NJ, et al. Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes. Int J Gen Med. 2014;7:89–101.
   PubMedGoogle Scholar
• Iurlo A, Cattaneo D. Treatment of myelofibrosis: old and new strategies. Clin Med Insights Blood Disord. 2017;10:1179545X17695233.
   PubMedGoogle Scholar
• Riou M, Seferian A, Savale L, et al. Deterioration of pulmonary hypertension and pleural effusion with bosutinib following dasatinib lung toxicity. Eur Respir J. 2016;48(5):1517–1519.
   PubMed Web of Science ®Google Scholar
• Hickey PM, Thompson AAR, Charalampopoulos A, et al. Bosutinib therapy resulting in severe deterioration of pre-existing pulmonary arterial hypertension. Eur Respir J. 2016;48(5):1514–1516.
   PubMed Web of Science ®Google Scholar
• Seegobin K, Babbar A, Ferreira J, et al. A case of worsening pulmonary arterial hypertension and pleural effusions by bosutinib after prior treatment with dasatinib. Pulm Circ. 2017;7(4):808–812.
   PubMed Web of Science ®Google Scholar
• Minami M, Arita T, Iwasaki H, et al. Comparative analysis of pulmonary hypertension in patients treated with imatinib, nilotinib and dasatinib. Br J Haematol. 2017;177(4):578–587.
   PubMed Web of Science ®Google Scholar
• Guignabert C, Phan C, Seferian A, et al. Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension. J Clin Invest. 2016;126(9):3207–3218.
   PubMed Web of Science ®Google Scholar
• Montani D, Bergot E, Günther S, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation. 2012;125(17):2128–2137.
   PubMed Web of Science ®Google Scholar
• Redfield MM, Jacobsen SJ, Burnett JC, et al. Burden of systolic and diastolic ventricular dysfunction in the community. JAMA. 2003;289(2):194–202.
   PubMed Web of Science ®Google Scholar
• Mosterd A, Hoes AW, De Bruyne MC, et al. Prevalence of heart failure and left ventricular dysfunction in the general population. The Rotterdam Study. Eur Heart J. 1999;20(6):447–455.
   Web of Science ®Google Scholar
• Vasan RS, Xanthakis V, Lyass A, et al. Epidemiology of left ventricular systolic dysfunction and heart failure in the framingham study: an echocardiographic study over 3 decades. JACC Cardiovasc Imaging. 2018;11(1):1–11.
   PubMed Web of Science ®Google Scholar
• Fischer M, Baessler A, Hense HW, et al. Prevalence of left ventricular diastolic dysfunction in the community: results from a Doppler echocardiographic-based survey of a population sample. Eur Heart J. 2003;24(4):320–328.
   PubMed Web of Science ®Google Scholar